Literature DB >> 29057359

Spinal metastases of two different grade oligodendrogliomas: a case report and review of literature.

Carlos Enrique Maiguel Carrizosa1, Maria Gabriela Sanchez Paez1, Andreina Martinez Amado2, Andrea Gonzalez Gutierrez3, Maria Emma Garcia Ardila4.   

Abstract

Oligodendrogliomas (OGD) are glial tumors, together with mixed oligoastrocytoma constituting 5-20% of all gliomas, which occur predominantly in younger populations and are managed with surgery and chemotherapy with good long-term prognosis after treatment and additionally present with low rates of metastases. We present the case of a 46-year-old patient with intracranial right frontal subcortical OGD [World Health Organisation (WHO) grade II] managed at the Neurosurgery Department in Foscal Clinic, Floridablanca, Colombia. Two years after brain surgery the patient presents with neurological symptomatology suggestive of spinal cord compression and is found to have a neoplastic lesion with extra medullary compressive strength on the conus medullary and wrapping all of the roots with the final report of pathology and immunohistochemistry indicating: OGD (WHO grade III), this lesion was the only one found, the brain studies shows any residual tumor or recurrence in the primary tumor site.

Entities:  

Keywords:  Oligodendrogliomas (OGD); extracranial metastases; low grade oligodendroglioma (low grade OGD); spinal cord metastases; two different grades of oligodendrogliomas (two different grades of OGD)

Year:  2017        PMID: 29057359      PMCID: PMC5637209          DOI: 10.21037/jss.2017.06.14

Source DB:  PubMed          Journal:  J Spine Surg        ISSN: 2414-4630


  15 in total

1.  EXTRA PRIMARY SEEDING OF GLIOBLASTOMA MULTIFORME IN THE SUBARACHNOID SPACE AND EPENDYMA.

Authors:  M T MOORE; G EISINGER
Journal:  Neurology       Date:  1963-10       Impact factor: 9.910

2.  Oligodendrogliomas; a review of 200 cases.

Authors:  F EARNEST; J W KERNOHAN; W M CRAIG
Journal:  Arch Neurol Psychiatry       Date:  1950-06

3.  Extracranial metastases from central nervous system tumors in children and adolescents.

Authors:  M T Gyepes; G J D'angio
Journal:  Radiology       Date:  1966-07       Impact factor: 11.105

4.  Symptomatic spinal cord metastasis from cerebral oligodendroglioma.

Authors:  A Elefante; C Peca; M L Del Basso De Caro; C Russo; F Formicola; G Mariniello; A Brunetti; F Maiuri
Journal:  Neurol Sci       Date:  2011-09-17       Impact factor: 3.307

Review 5.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.

Authors:  David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison
Journal:  Acta Neuropathol       Date:  2016-05-09       Impact factor: 17.088

Review 6.  From the archives of the AFIP: Oligodendroglioma and its variants: radiologic-pathologic correlation.

Authors:  Kelly K Koeller; Elisabeth J Rushing
Journal:  Radiographics       Date:  2005 Nov-Dec       Impact factor: 5.333

7.  Extraneural metastases of anaplastic oligodendroglioma.

Authors:  Seong Rok Han; Sang Won Yoon; Gi Taek Yee; Chan Young Choi; Dong Joon Lee; Moon Jun Sohn; Sun Hee Chang; Choong Jin Whang
Journal:  J Clin Neurosci       Date:  2008-02-15       Impact factor: 1.961

8.  Unusual patterns of recurrence in low grade gliomas.

Authors:  Jonathan R Ellenbogen; Peter Davies; Paul R Eldridge; Michael D Jenkinson
Journal:  J Clin Neurosci       Date:  2013-10-15       Impact factor: 1.961

Review 9.  Occipital anaplastic oligodendroglioma with multiple organ metastases after a short clinical course: a case report and literature review.

Authors:  Gang Li; Zhiguo Zhang; Jianghong Zhang; Tianbo Jin; Hongjuan Liang; Li Gong; Guangbin Cui; Haixia Yang; Shiming He; Yongsheng Zhang; Guodong Gao
Journal:  Diagn Pathol       Date:  2014-01-21       Impact factor: 2.644

Review 10.  Imaging of oligodendroglioma.

Authors:  Marion Smits
Journal:  Br J Radiol       Date:  2016-02-05       Impact factor: 3.039

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.